Source link : https://www.newshealth.biz/health-news/no-benefit-with-pamrevlumab-in-pancreatic-cancer/
The results of the global phase 3 LAPIS trial suggest that the addition of pamrevlumab to standard chemotherapy fails to improve survival outcomes in patients with locally advanced pancreatic cancer (LAPC) despite promising early-phase results. The findings highlight the ongoing challenges in developing effective treatments for this aggressive disease, according to lead investigator Vincent J. […]
Author : News Health
Publish date : 2025-01-29 11:30:33
Copyright for syndicated content belongs to the linked Source.